RU2013141559A - Способ ингибирования клеток опухоли гамартомы - Google Patents

Способ ингибирования клеток опухоли гамартомы Download PDF

Info

Publication number
RU2013141559A
RU2013141559A RU2013141559/04A RU2013141559A RU2013141559A RU 2013141559 A RU2013141559 A RU 2013141559A RU 2013141559/04 A RU2013141559/04 A RU 2013141559/04A RU 2013141559 A RU2013141559 A RU 2013141559A RU 2013141559 A RU2013141559 A RU 2013141559A
Authority
RU
Russia
Prior art keywords
syndrome
represents hydrogen
compound
trifluoromethyl
halogen
Prior art date
Application number
RU2013141559/04A
Other languages
English (en)
Russian (ru)
Inventor
Джин Дж. ЧЖАО
Ци ВАН
Original Assignee
Дана-Фарбер Кэнсер Инститьют, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дана-Фарбер Кэнсер Инститьют, Инк. filed Critical Дана-Фарбер Кэнсер Инститьют, Инк.
Publication of RU2013141559A publication Critical patent/RU2013141559A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2013141559/04A 2011-02-11 2012-02-09 Способ ингибирования клеток опухоли гамартомы RU2013141559A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441896P 2011-02-11 2011-02-11
US61/441,896 2011-02-11
PCT/US2012/024440 WO2012109423A1 (en) 2011-02-11 2012-02-09 Method of inhibiting hamartoma tumor cells

Publications (1)

Publication Number Publication Date
RU2013141559A true RU2013141559A (ru) 2015-03-20

Family

ID=45809596

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013141559/04A RU2013141559A (ru) 2011-02-11 2012-02-09 Способ ингибирования клеток опухоли гамартомы

Country Status (11)

Country Link
US (1) US20140309221A1 (cg-RX-API-DMAC10.html)
EP (1) EP2673268A1 (cg-RX-API-DMAC10.html)
JP (1) JP2014505107A (cg-RX-API-DMAC10.html)
KR (1) KR20140063509A (cg-RX-API-DMAC10.html)
CN (1) CN103476765A (cg-RX-API-DMAC10.html)
AU (1) AU2012214413A1 (cg-RX-API-DMAC10.html)
BR (1) BR112013020159A2 (cg-RX-API-DMAC10.html)
CA (1) CA2826387A1 (cg-RX-API-DMAC10.html)
MX (1) MX2013009256A (cg-RX-API-DMAC10.html)
RU (1) RU2013141559A (cg-RX-API-DMAC10.html)
WO (1) WO2012109423A1 (cg-RX-API-DMAC10.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
CN103012284A (zh) * 2012-12-26 2013-04-03 无锡捷化医药科技有限公司 一种2-氨基-5-溴嘧啶类化合物的制备方法
CA2903979A1 (en) 2013-03-14 2014-09-18 Novartis Ag 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
BR112016023811B8 (pt) 2014-04-22 2023-01-10 Piqur Therapeutics Ag Método para fabricação para derivados de triazina, pirimidina e piridina, seus intermediários e seus métodos de fabricação
CN105001151B (zh) * 2015-08-28 2017-07-14 苏州明锐医药科技有限公司 布帕尼西中间体及其制备方法
EP3458035B1 (en) * 2016-05-18 2026-08-19 Torqur AG Bimiralisib and derivatives thereof for use in the treatment of actinic keratosis
KR102483630B1 (ko) * 2016-05-18 2023-01-02 토르쿠르 아게 피부 병변의 치료
CN106905294A (zh) * 2016-07-08 2017-06-30 苏州科睿思制药有限公司 5‑[2,6‑二(4‑吗啉基)‑4‑嘧啶基]‑4‑(三氟甲基)‑2‑吡啶胺的晶型及其制备方法
CN106632443B (zh) * 2016-11-23 2022-06-17 山东友帮生化科技有限公司 一种2-氨基嘧啶-5-硼酸频哪酯硼酸盐的合成方法
BR112020009855A8 (pt) * 2017-11-23 2023-01-10 Piqur Therapeutics Ag Tratamento de distúrbios de pele
CN114213340B (zh) 2022-02-22 2022-06-07 北京蓝晶微生物科技有限公司 2,4-二氨基嘧啶氧化物的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20120640A1 (es) * 2009-07-02 2012-06-09 Sanofi Sa Nuevos derivados de (6-oxo-1,6-dihidro-pirimidin-2-il)-amida, su preparacion y su utilizacion farmaceutica como inhibidores de fosforilacion de akt (pkb)

Also Published As

Publication number Publication date
KR20140063509A (ko) 2014-05-27
CN103476765A (zh) 2013-12-25
EP2673268A1 (en) 2013-12-18
CA2826387A1 (en) 2012-08-16
MX2013009256A (es) 2013-12-09
BR112013020159A2 (pt) 2016-11-08
JP2014505107A (ja) 2014-02-27
WO2012109423A1 (en) 2012-08-16
AU2012214413A1 (en) 2013-08-22
US20140309221A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
JP2014505107A5 (cg-RX-API-DMAC10.html)
UY30809A1 (es) Derivados de n-[3-[4-fenil)piperidin-1-carbonil]fenil]sulfonamidas sustituidas, procesos de preparacion y aplicaciones
RU2011151835A (ru) Пиразолопиримидины и родственные гетероциклы как ингибиторы киназ
GEP20156389B (en) Oxazolidin-2-one compounds and their usage as pi3ks inhibitors
JP2014511892A5 (cg-RX-API-DMAC10.html)
JP2013510123A5 (cg-RX-API-DMAC10.html)
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
JP2008535902A5 (cg-RX-API-DMAC10.html)
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
RU2013108348A (ru) Конденсированные гетероарилы и их применение
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
PH12015500719A1 (en) Gdf-8-inhibitors
EA201490673A1 (ru) Производные пирролопиримидина и пурина
JP2013531029A5 (cg-RX-API-DMAC10.html)
EA201201680A1 (ru) Морфолинопиримидины и их применение в терапии
TW200833663A (en) Therapeutic agents
RU2014152790A (ru) Пирролопиразоновые ингибиторы танкиразы
RU2013127655A (ru) Фармацевтическая комбинация паклитаксела и ингибитора cdk
JP2017514809A5 (cg-RX-API-DMAC10.html)
EA201290976A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
NZ607580A (en) N-heteroaryl compounds
JP2011521938A5 (cg-RX-API-DMAC10.html)
JP2012512863A5 (cg-RX-API-DMAC10.html)
MX340233B (es) Agonistas de receptores de neurotrofina y sus usos como medicamentos.

Legal Events

Date Code Title Description
FA94 Acknowledgement of application withdrawn (non-payment of fees)

Effective date: 20160316